Butyrate is a key bioactive product of dietary fibre fermentation thought to play a key role in cancer prevention. One contributory mechanism in this role is the regulation of apoptosis by butyrate. As butyrate shows low levels of toxicity, the mechanisms by which it triggers or regulates apoptosis are of great interest. We and others have shown that the proapoptotic protein BAK is upregulated by butyrate. We show here that this observation is conserved across multiple cell lines, that it occurs in all cells in a population and is at the transcriptional level. We have used a promoter-reporter construct to identify the regulatory regions of the BAK promoter and found that much of the transcriptional activity occurs via a single Sp1/Sp3 binding site. We have shown that both Sp1 and Sp3 bind, but upon butyrate treatment Sp1 binding decreases in favour of Sp3 binding. We speculate that this may be an acetylation-mediated event.
Introduction
There is substantial epidemiological evidence to suggest that dietary fibre plays a critical role in the prevention of colorectal cancer. A number of studies over the last three decades have shown that fibre may suppress colorectal carcinogenesis (Hill, 1997) . These have been borne out with publication of data from a large pan-European prospective cohort study (Bingham et al., 2003) . Although some major intervention studies failed to support a role for fibre in adenoma prevention (Bonithon-Kopp et al., 2000; Schatzkin et al., 2000) , reservations have been made about the scope of their interpretation (Hill, 2002; Arasaradnam et al., 2004) . Studies in rats have shown convincingly that fibre, specifically fermentable fibre, protects against carcinogen-induced tumorigenesis (McIntyre et al., 1993) . Of all the fermentation products of fibre, butyrate appears to be the key bioactive agent (McIntyre et al., 1993; Perrin et al., 2001) . In addition to its cancer preventing function, butyrate is thought to regulate normal colon physiology and tissue homeostasis (Hass et al., 1997) including both cell division and apoptosis (Hague et al., 1993) . Loss of normal regulation of cell division and an increased resistance to apoptosis are both hallmarks of cancer and potential key points at which butyrate may exert its anticarcinogenic function.
Butyrate is an inhibitor of HDACs at millimolar concentrations (which are known to be achievable in the colon and are therefore physiologically relevant). In vitro studies of the cellular response to HDAC inhibition (by butyrate or trichostatin A) indicate that large number of genes' expression are altered, with around 5% of all genes changed by two-fold or more (Mariadason et al., 2000; Della Ragione et al., 2001) . The underpinning mechanisms include increased access of transcription factors to nucleosomally located binding sites through displacement of histone N-termini by acetylation, movement of nucleosomes and through direct activation or inactivation of cognate regulatory binding proteins. A number of studies addressing the mechanisms by which butyrate drives cell-cycle arrest have identified transcriptional upregulation of p21 as a key event. The inhibition of HDAC1 in the transcription complex occupying Sp1 binding sites in the p21 promoter seems sufficient to allow upregulation of transcription (Siavoshian et al., 2000; Blottiere et al., 2003) .
The Bcl2 family of proteins is diverse but broadly falls into three groups -Bcl2-like anti-apoptotic proteins, Bax-like pro-apoptotic proteins, which facilitate cytochrome c release from the mitochondria and BH3-only proteins which act to signal damage to the other two groups and repress, or activate their function. The Bax-like group is select having three members, Bax, BAK and Bok. Bax and BAK have widespread tissue distribution and both are expressed in the colon (Potten et al., 1997) . They are therefore candidate regulators of the normal colonic response to carcinogens.
Determining the mechanism of action of butyrate in inducing apoptosis is intriguing for several reasons. The role for butyrate in cancer prevention may be due, at least in part, to its function in regulating apoptosis. However, it is also possible that butyrate functions to kill cells by a different mechanism of action to cytotoxic drugs. In the case of cytotoxics, damage signals arising following an insult trigger the activation of latent pro-apoptotic Bcl2 family proteins in the cell (Griffiths et al., 1999 . Although damage may occur at any number of loci within the cell, the Bcl2 family acts as integrators of damage signalling as well as effectors of the apoptotic response . In contrast, studies of butyrate's toxicity have concluded that it is either very low or non-toxic although few, if any, studies have been based on toxicity assays (Welter et al., 1991) . It would therefore seem unlikely that a damage-signalling pathway could be invoked to explain butyrate-mediated cell death. Furthermore, using a rat model of carcinogenesis, Le Leu et al. (2002 Leu et al. ( , 2003 concluded that direct induction of apoptosis may not be the physiologically relevant mechanism of cancer prevention. Rather it is the sensitization of cells to damage and reduction of the apoptotic threshold, mediated by butyrate, which appears to underwrite cancer prevention in vivo. Elucidation of the mechanism of triggering apoptosis may also reveal how butyrate acts to sensitize cells to damage and therefore improve the apoptotic response.
We have investigated the mechanism of action of butyrate in triggering apoptosis in a panel of colorectal cell lines to avoid typological results; in particular, we have studied the dysregulation of Bcl2 family proteins in order to identify potential effectors of the apoptotic response. We have assessed the importance of gene dysregulation in triggering apoptosis and have determined the mechanisms by which it occurs.
Results

Butyrate induces apoptosis without cell damage
The cell lines HCT116, HT29 and Caco2 were treated with a range of butyrate concentrations between 0 and 10 mM. Concentrations of 5 mM and over were found to reduce the attached cell count 48-72 h after treatment in all cell lines (Figure 1a) . Detached cells had a characteristic condensed, fragmented nuclear morphology and PARP cleavage occurred indicating that cell loss was by apoptosis (Figure 1b) . Next we sought to determine whether butyrate was driving apoptosis through a damage mechanism. We undertook clonogenic assays on cells treated with 5 mM butyrate, a concentration inducing 60-80% apoptosis at 48 h, for times between 0 and 48 h. When plotted on a 2-log scale ( Figure 2a ) there was negligible decrease in cloning efficiency at any time point up to and including 48 h. When the same data were plotted on a linear scale, loss in cloning was only observed 24-48 h after treatment and corresponded with loss of viable cells by apoptosis as measured by reduction in attached cell count after the same treatment. Taken together our data indicate that butyrate is a potent inducer of apoptosis, but that this induction occurs in the absence of significant damage.
Butyrate induces apoptosis through upregulation of BAK
We assessed the effect of butyrate upon Bcl2 family proteins. The levels of BAK, Bax and BclxL were assessed by Western blotting protein from cells treated with either 0.5 mM butyrate, which induced cytostasis or 5 mM butyrate, which induced apoptosis and harvested after 24 or 48 h. All the three cell lines showed an increase in BAK levels in response to butyrate (Figure 3a) . In HCT116 and HT29 this was evident at 0.5 mM and marked at 5 mM. In Caco2 there was a slight increase at 5 mM, and a clear increase at 25 mM (25 mM data not shown). All the three cell lines showed a reduction in BclxL levels which was evident at at 5 mM (Figure 3a) . In contrast to the change in BAK and BclxL, cellular levels of Bax were unchanged after treatment. Next we quantified BAK upregulation in HCT116 cells by flow cytometry (Figure 3b ). In agreement with the western-blot data, both cytostatic and pro-apoptotic concentrations of butyrate were found to upregulate BAK, with the largest increase being after 48 h treatment with 5 mM butyrate. The whole BAK-staining histogram shifted after treatment, indicating all cells in the population upregulated BAK, rather than any one sub-population (e.g., cell-cycle phase). The median intensity of the histograms before and after treatments was measured in each of three independent repeat experiments. Mean values and standard experimental errors result showed that the upregulation of BAK is significant at both cytostatic and pro-apoptotic concentrations of butyrate ( Figure 3c , inset panel).
As butyrate can act to enhance transcription (Mariadason et al., 2000) , we wished to determine whether the observed increase in BAK was due to an increase at the RNA level. Using qRT-PCR, the upregulation of BAK was determined as 123% over untreated cells (P ¼ 0.086); furthermore, qRT-PCR indicated that Bax is also transcriptionally upregulated by 140% (P ¼ 0.029 - Figure 3d ). The stable levels of Bax protein imply that regulation also occurs at the post-transcriptional level. Given the constancy of cellular levels of Bax in conjunction with a dependence of butyrate upon protein synthesis to trigger apoptosis (Ruemmele et al., 1999; and see below) , we asked what the contribution of Bax is to rates of apoptosis. HCT116 cells either carrying or lacking Bax (Zhang et al., 2000) were treated with 5 mM butyrate. After 48 h treatment Bax À/À cells showed less apoptosis than their parental control cell line, but by 72 h the level of apoptosis in Bax null cells was restored ( Figure 3e ).
These data suggest that the dysregulation of BAK and BclxL in response to butyrate are conserved events that occur in multiple cell lines. All cells in a population alter their BAK in response to butyrate and this appears to be a transcriptionally mediated event as it occurs at the mRNA level. Bax levels were unchanged by butyrate treatment and the removal of Bax slowed, but did not block, apoptosis indicating this is potentially a Bax-independent pathway. We also noted that even at sub-apoptotic concentrations of butyrate there were significant changes in BAK and BclxL levels. Butyrate-mediated apoptosis is not associated with a loss in clonogenicity. Cell lines (HCT116 and HT29) were treated with 5 mM butyrate for the times indicated and clonogenicity measured after treatment. Cloning efficiency was plotted on a log scale (a) and linear scale (b). Cell detachment, a proxy measure of apoptosis, was determined for the same cell lines and time points and butyrate concentration (c).
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BAK dysregulation is dependent upon protein synthesis
Previous studies have shown that the translation inhibitor cycloheximide (CHX) can block butyratemediated apoptosis (Ruemmele et al., 1999) . We found that 1 mg/ml CHX significantly reduced the level of apoptosis induced by 5 mM butyrate (Figure 4a ). Higher Upregulation of BAK by butyrate in the colon H Chirakkal et al concentrations of CHX were pro-apoptotic even in the absence of butyrate(data not shown). HCT116 cells were treated with 1 mg/ml CHX and 5 mM butyrate for 24 and 48 h and the levels of BAK determined by Western blotting (Figure 4b ). We found that BAK upregulation was inhibited by CHX. The inhibition of BAK upregulation was also observed by flow cytometry and found to be significant (Figure 4c ). These data consolidate the importance of transcriptional upregulation of BAK, as the lack of upregulation in the absence of de novo synthesis implies no role for protein stabilization. We infer from the observation that CHX inhibits downregulation of BclxL, that downregulation is not attributable to normal half-life decay alone, and that an as-yet-unidentified active mechanism is involved in BclxL degradation, which is butyrate-regulated.
Regulation of bak transcription by butyrate As both Bcl2 and Bclx are transcriptionally regulated through multiple promoters (Young and Korsmeyer, 1993; MacCarthy-Morrogh et al., 2000) , we assessed whether there were multiple transcriptional startpoints for bak by 5 0 RACE (Figure 5a) . Data indicate that all bak transcription in this cell line occurs from a single startpoint and that this is unaltered by butyrate treatment. Secondary bands appearing were not-specific to bak.
Next we sought to analyse the genetic regulation of the bak gene. A 4598 bp fragment of the bak promoter, spanning À2018 to the ATG ( þ 2580) and including the complete 5 0 UTR was cloned into pbgal-Basic (Figure 5b) . The promoter-reporter construct was transfected into HCT116 cells and the time-and concentration-dependency of butyrate-mediated transcription was analysed by b-galactosidase activity assay. Increases in activity occurred between 12 and 24 h after addition of butyrate in a concentrationdependent manner (Figure 5c ). At 48 h maximal activity was observed in cells treated with 2 mM butyrate ( Figure 5d ) owing to the cell loss caused by apoptosis at higher concentrations of butyrate (Figure 1a) . In order to identify the region of the promoter responsible for bak regulation and butyrate-mediated up-regulation, we generated a series of nested deletions through the promoter. Deletion of the upstream sequence to within 174 bp of the transcriptional startpoint had no effect upon either basal expression of b-galactosidase or upregulation by butyrate. However, deletions beyond this point abrogated both (Figure 6a , compare deletion N9 with deletion N10). Analysis of the sequence around the startpoints of deletions N9 and N10 revealed three Sp1/Sp3 binding sites (labelled SpA, SpB and SpC in Figure 6b) . A further series of deletions (N9a-N9d) were made across this region and the expression and inducibility of lacZ were measured. Clone N9a only lacks the SpB site relative to N9 but has lost nearly all basal expression, indicating that this site is central to the regulation of bak expression (Figure 6c ).
Upregulation of bak is triggered by increased Sp3 binding
In order to determine the transcription factors responsible for bak upregulation we undertook an electrophoretic mobility shift assay (EMSA). A biotinylated probe sequence carrying all three Sp1/Sp3 sites was incubated with nuclear extract from untreated and butyrate-treated HCT116 cells. A multisite probe was chosen in order to optimize potential Sp3 binding (Bouwman and Philipsen, 2002) . The amount of probe retarded by nuclear extract alone increased following butyrate treatment (Figure 7a, compare lanes 1 and 4) . Both Sp1 and Sp3 from untreated nuclear extract appeared to bind probe; however, after treatment, while Sp1 binding appeared constant (compare lanes 2 and 5), Sp3 binding increased substantially (compare lanes 3 and 6). In order to identify which shifted bands were bound by which transcription factor and better to quantify changes in binding, we repeated the mobility 
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H Chirakkal et al shift assay, followed by a western transfer and immunoprobing with either Sp1 or Sp3. Two sets of samples were run on a single gel and transferred to a single membrane by western transfer before cutting the membrane and separate immunoprobing for Sp1 or Sp3. This allowed alignment of the separate blots. Data show two shifted bands contain Sp3, but only one contained Sp1 (Figure 7b ). The Sp1 and upper Sp3 bands aligned exactly, indicating they may be part of the same transcriptional complex. We noted that after treatment, Sp1 cross-reactivity decreased, whereas Sp3 increased. We quantified change relative to bound Sp factor in untreated cell extract and found around a 25% decrease in Sp1 signal and a 34% increase in Sp3 signal. Taken together these data indicate that bak is regulated through Sp1 sites around À166 bp and that upregulation of bak appears to be through increased Sp3 binding of this sequence.
Discussion
Butyrate is a non-cytotoxic product of fibre fermentation in the colon, which is thought to play a key role in the prevention of colorectal cancer. This role is exerted through a number of potential mechanisms, including driving cell-cycle arrest and regulating apoptosis. In order to investigate the mechanism by which butyrate induces apoptosis we have analysed the regulation of Bcl2 family proteins in three colorectal cell lines.
Critically, in all lines we examined, we found BAK was upregulated and Bax levels were unaltered, suggesting that this is a conserved response, not cell line-specific typology. Apoptosis in response to butyrate is inhibitable by CHX, from which we infer that the increased BAK levels are through de novo synthesis rather than stabilization. The level of Bax, the only other BH1-2-3 protein normally found in colorectal tissue, was unaffected by butyrate treatment and deletion of Bax slowed but did not abrogate apoptosis. We infer a central role for upregulation of BAK as an underlying mechanism in the triggering of cell death by butyrate.
Our data indicate that BAK is upregulated at the transcriptional level through increased binding of transcription factor to the Sp1/Sp3 site cluster around À172. This places bak in an emerging group of genes which are upregulated by butyrate through Sp1/ Sp3 sites. Other members of this regulon include p21 (Blottiere et al., 2003) , MVP (Steiner et al., 2004) , HMG CoA-synthase (Camarero et al., 2003) , GADD45 ( Hirose et al., 2003) , KLF4 (Chen et al., 2004) . Several of these genes play a known and central role in regulating cell fate and the addition of bak to this family consolidates the importance of Sp1 and Sp3 as effectors of a 'butyrate response'. Furthermore, the upregulation of p21 in response to butyrate occurs, analogous to bak, through increased Sp3 binding at the promoter (Sowa et al., 1999) . The mechanisms by which butyrate regulates Sp1/3 function are not clear. Sp3 is known to be acetylated but available data indicates that acetylation suppresses function (Braun et al., 2001) , which may exclude it as a mechanism in this context. Our data strongly suggest that bak upregulation is mediated through increased Sp3 binding at the promoter region rather than Sp1 binding, which decreased after treatment with butyrate (Figure 7b and c) . In contrast to Sp1, which effectively binds single sites, Sp3 binding is more effective in the presence of multiple consensus sequences. The N9 deletion did not abrogate either expression or induction of bak; however, we cannot exclude a role for the binding sites flanking Sp-B, particularly Sp-C, in enhancing Sp3 binding. Detailed dissection of this binding is the subject of our continuing study. Nevertheless, there appears to be a conserved mechanism governing the regulation of cell fate and mediated through activation of Sp1/Sp3 in response to butyrate in the colon reflecting an evolutionary adaptation to colonic fermentation. We noted with particular interest the significant, but modest, upregulation of BAK in cells treated with a subapoptotic concentration of butyrate. Several studies have shown that the cancer preventive effect of butyrate is associated with an increased sensitivity to damage. Increased levels of butyrate alone did not increase levels of apoptosis in colon crypts of rats on a high-fibre diet. However, when animals were treated with a carcinogen, levels of crypt apoptosis were higher in fibre-fed rats than in low-fibre controls (Le Leu et al., 2002 Leu et al., , 2003 . We observed increased BAK and reduced BclxL in response to sub-apoptotic concentrations of butyrate (Figure 3a-d) . This would be a candidate mechanism for the observed in vivo effect through resetting the 'apopstat' -the balance between pro-and anti-apoptotic proteins (Oltvai and Korsmeyer, 1994) and thereby a contributory mechanism to the cancer preventing action of the dietary fibre. Taken together our data imply a critical role for BAK in the induction of apoptosis by butyrate, and suggest a physiological mechanism by which the colon epithelium may become sensitized to damage by consumption of fibre. We hypothesize that the upregulation of proapoptotic proteins may indicate a different mechanism of action of cell death in comparison with cytotoxin damage-triggered apoptosis. Dissecting this pathway is the subject of our continuing enquiry.
Materials and methods
Cell culture and cell analysis HCT116, HT29 and Caco2 and HCT116 Bax À/À cells were cultured in DMEM (Gibco, Paisley, UK), 10% fotal calf serum (Harlan Seralabs, Bicester, UK) and Penicillin/Streptomycin (Gibco, Paisley, UK). Butyrate and cycloheximide (both Sigma, Poole, UK) were added as appropriate. Flow cytometry for BAK was as previously described (Griffiths et al., 1999) , using Calbiochem BAK polyclonal antibody (6036E). Clonogenic assays were undertaken as previously described (Makin et al., 2001) . 
Western blotting
Protein extracts from cells were prepared in kinase buffer, as previously described . Proteins were separated on SDS-PAGE gels and transferred to PVDF membranes for immunoprobing. Probing was essentially as previously described (Griffiths et al., 1999) . Antibodies used were: BAK (AB-1, Oncogene research products, Nottingham, UK), Bax (N20, Santa Cruz Biotechnology, Santa Cruz, CA, USA), Actin (AC40, Sigma), Bclx (Transduction Labs, Oxford, UK) Sp1 (PEP2, Santa Cruz Biotechnology), Sp3 (D-20, Santa Cruz Biotechnology). Cross-reactions were visualized using HRP-conjugated secondary antibodies (Sigma), SuperSignal West ECL reagent (Pierce, Cramlington, UK) and a Chemigenius BioImaging system (Syngene, Cambridge, UK).
Molecular methods
The BAK promoter region (À2018 to þ 2580) was amplified by PCR using KOD HotStart DNA polymerase (Novagen, Nottingham, UK), from a PAC clone carrying the genomic region (kindly provided by the Sanger Centre, Cambridge, UK). The PCR product was cloned into pbgal-Basic (BD Biosciences, Oxford, UK) and sequenced to ensure fidelity of the PCR reaction. Smaller nested deletion derivatives were generated by PCR of the promoter region and re-sequenced before cloning into pbgal. Transient transfections of HCT116 were undertaken in 96-well plates using SuperFect (Qiagen, Crawley, UK). LacZ assays were performed using a fluorescent substrate, MUG, as previously described (Corfe et al., 1994) . Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was carried out on total RNA extracted using Trizol reagent (Invitrogen, Paisley, UK) according to manufacturer's instructions. RNA was extracted from three independent experiments and was subjected to DNase treatment. The DNA-free RNA samples were reverse transcribed using Superscript III (Invitrogen) and random hexamers (Promega, Southampton, UK). The cDNA was pooled and then assayed in three independent experiments with three replicates for each sample. Predesigned primer pairs for Bax, Bak and Beta-actin were purchased from the QuantiTect range (Qiagen). Primer annealing conditions were empirically optimized to give a single product and RNA concentration and cycle number were optimized to be in the linear range. Amplification was performed using Quantitect SYBR green mix (Qiagen) on the MX3000P platform (Stratagene, La Jolla, CA, USA) according to manufacturer's instructions.
EMSA-ready nuclear extracts were prepared from cells using ActiveMotif nuclear preparation kit (ActiveMotif, Rixensart, Belgium). Oligonucleotides were biotin labelled and purchased from Sigma-Genosys. Sp1 and Sp3 supershift antibodies were used (PEP2 and D-20, respectively; Santa Cruz Biotechnology). EMSA reactions were performed using LightShift chemiluminescent EMSA (Pierce) as per manufacturer's recommendations.
